AltuCell Therapeutics Announces Proof-of-Concept in Lead Programs in Type 1 Diabetes in Human Subjects; Phase 1 Pilot in Humans Has IND Approval & Trial to Begin Shortly
AltuCell Therapeutics, Inc., AltuCell announced today the achievement of approval of IND in Italy after pre-clinical proof-of-concept based on data from its two lead programs for type 1 diabetes testing of cadaver stem cell-derived islets in both human and non-human subjects. Their capsules have been implanted in people with diabetes for 5 year, demonstrating long-term safety, with no toxicity or tissue necrosis, and no rejection in any of the patients treated. - January 15, 2021
Press Releases 1 - 1 of 1